MYGN
MYRIAD GENETICS INC
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeMyriad reported a significant Q2 2026 miss (EPS $0.25 loss vs. $0.06 consensus) with 11% YoY revenue decline driven by prenatal test weakness, prompting a steep $90M guidance cut (~10% of prior midpoint). The company is undergoing a strategic review while managing commercial leadership changes, though oncology pipeline investments (Prolaris+AI, Precise MRD expansion) continue.
Red flags
- •EPS miss of 317% ($0.25 loss vs. $0.06 consensus estimate)
- •Revenue guidance cut by $90M (10.5% reduction from prior $860-880M range to $770-790M)
- •11% YoY revenue decline with 9% average revenue per test decrease
- •49% stock price drop following earnings
- •Prenatal testing segment weakness creating structural headwind
- •Commercial leadership change (CCO departure, new EVP Commercial appointed)
- •Strategic review process signals management uncertainty about current business model
Fund 13D/13G Filings (2)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Glenview Capital | SC 13G/A | — | 0.0% | +38.1% vs SPY +38.6% abs | 2026-08-14 | ↗ |
| Glenview Capital | SC 13G | NEW | 5.3% | — | 2026-01-13 | ↗ |
Tracked Funds Holding (1)
| Fund | Manager | Shares Held | Position Value |
|---|---|---|---|
| Point72 | Steve Cohen | 239K | $1M |
Quarter-end 13F positions for the tracked funds holding this stock.